These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Walz G Nephrol Dial Transplant; 2006 Jul; 21(7):1752-7. PubMed ID: 16705023 [No Abstract] [Full Text] [Related]
3. Role of vasopressin antagonists. Torres VE Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616 [TBL] [Abstract][Full Text] [Related]
8. [Autosomal dominant polycystic kidney disease: new insights and possible drugs]. Meijer E; de Jong PE; van der Jagt EJ; Peters Do; Breuning MH; Gansevoort RT Ned Tijdschr Geneeskd; 2009 May; 153(20):968-74. PubMed ID: 19490717 [No Abstract] [Full Text] [Related]
10. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Meijer E; Gansevoort RT; de Jong PE; van der Wal AM; Leonhard WN; de Krey SR; van den Born J; Mulder GM; van Goor H; Struck J; de Heer E; Peters DJ Nephrol Dial Transplant; 2011 Aug; 26(8):2445-53. PubMed ID: 21393612 [TBL] [Abstract][Full Text] [Related]